Research News

Brain represented as leaves on a tree being held by a trunk and branches represented as hands.

Shedding light on severe MS
10/25/24
UB studies of this rare form of the disease show that grey matter volume, not lesions, are key in severe MS and that novel tools can better assess them.

10/25/24 Read more

Labs find key metabolic regulators of drug resistance in pancreatic cancer
12/13/22
The team found several therapeutic vulnerabilities of drug resistance that could be targeted to improve outcomes.
Brashear is elected to AAMC Council of Deans board
12/8/22
The council provides a national forum where medical school deans address critical issues facing academic medicine.
UB PhD student receives DOE research award
12/8/22
Nicholas Cucciniello will use the award to do thesis-related work at Los Alamos National Laboratory.
Scientist receives NIH Emerging Global Leader Award
12/7/22
UB CIGBS scholar Waheed Adedeji will investigate the influence of antidepressants on HIV medication among patients in Nigeria.
New tool developed for Kawasaki disease
12/6/22
The UB-developed scoring system is twice as accurate at predicting antibody resistance among U.S. children with the rare disease.
Fliesler recognized for retina research
12/5/22
The SUNY Distinguished Professor has been named the 2022 recipient of the Retina Research Foundation’s Paul Kayser International Award in Retina Research.
An alternative method to map neuron activity
12/2/22
A paper published recently by UB mathematicians suggests that “hypergraphs”
better explain how neuronal networks communicate.
Local teens with obesity see dramatic weight loss in trial
12/2/22
The results of a UB clinical trial on the drug semaglutide turned out to be better than anything the participants — or researchers — expected.
Study examines pre-quit time of smoking cessation drug
12/1/22
A UB-led study found that extending the pre-quit duration of a leading smoking cessation medication doesn’t help smokers quit.
Company addressing opioid issue with tech licensed from UB
12/1/22
Channavix Therapeutics and Peregrine BioVentures are developing patent families related to long-lasting, non-addictive pain therapeutics.

Next> <Previous